Vasileios Issaris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vasileios Issaris has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Alice Georgia Vassiliou
1st Department of Critical Care Medicine, Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens, 10676 Athens, Greece
8 shared publications - Charikleia Spyridon Vrettou
1st Department of Critical Care Medicine, Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens, 10676 Athens, Greece
8 shared publications - Georgios Poupouzas
1st Department of Critical Care Medicine, Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens, 10676 Athens, Greece
8 shared publications - Ioanna Dimopoulou
First Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
7 shared publications - Anastasia Kotanidou
1st Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, Athens, Greece
5 shared publications - Chrysi Keskinidou
1st Department of Critical Care Medicine, Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens, 10676 Athens, Greece
5 shared publications
Latest Publications
- 23 October 2026
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 33
Development of New Classes and Reassessment of Widely Used Drugs for the Management of Stable Chronic Obstructive Pulmonary Disease (COPD): Where Do We Stand?
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide. Bronchodilators remain the cornerstone of treatment due to the markable therapeutic effect of these drugs. Long-Acting β2-Adrenoreceptor agonists (LABAs) and Long-Acting Muscarinic Acetylcholine receptor antagonists (LAMAs) relieve bronchospasm, reduce air trapping, improve dyspnea, and reduce exercise intolerance. Despite the gradual, remarkable improvement in inhalation devices and the extended duration of action of newer agents, the β2-adrenoreceptor class may exhibit a reduced bronchodilator effect over time. Moreover, COPD is a complex, chronic inflammatory airway disease, often associated with multiple comorbidities and safety concerns related to the long-term use of currently available bronchodilators, further underscoring the need for new therapeutic classes. Consequently, there is growing interest in developing novel agents to expand treatment options and improve outcomes in COPD.
- 23 October 2026
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 33
Development of New Classes and Reassessment of Widely Used Drugs for the Management of Stable Chronic Obstructive Pulmonary Disease (COPD): Where Do We Stand?
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide. Bronchodilators remain the cornerstone of treatment due to the markable therapeutic effect of these drugs. Long-Acting β2-Adrenoreceptor agonists (LABAs) and Long-Acting Muscarinic Acetylcholine receptor antagonists (LAMAs) relieve bronchospasm, reduce air trapping, improve dyspnea, and reduce exercise intolerance. Despite the gradual, remarkable improvement in inhalation devices and the extended duration of action of newer agents, the β2-adrenoreceptor class may exhibit a reduced bronchodilator effect over time. Moreover, COPD is a complex, chronic inflammatory airway disease, often associated with multiple comorbidities and safety concerns related to the long-term use of currently available bronchodilators, further underscoring the need for new therapeutic classes. Consequently, there is growing interest in developing novel agents to expand treatment options and improve outcomes in COPD.
- Open Access
Growth Hormone–Insulin-like Growth Factor Axis and GDF-15 in Critical Illness: Implications for Survival Stratification
Background: The growth hormone (GH)–insulin-like growth factor (IGF) axis is profoundly dysregulated in critical illness. GDF-15 and individual IGF-binding proteins (IGFBPs) have separately been proposed as prognostic biomarkers, but to our knowledge, no prior study has simultaneously characterized all major GH–IGF axis components and GDF-15 in the same critically ill cohort, precluding assessment of their joint intercorrelation structure. Aim: To provide the first simultaneous characterization of the intercorrelation structure among ten GH–IGF axis components and GDF-15 in a single ICU cohort, testing whether this structure is robust to adjustment for illness severity; and, secondarily, to describe admission discriminatory performance relative to APACHE II and SOFA. Methods: This was a prospective observational pilot study of 43 critically ill adults with admission (T01) measurement of ten GH–IGF axis biomarkers and longitudinal follow-up to day 15. Spearman correlations and hierarchical clustering characterized the admission intercorrelation structure; partial correlations adjusting for APACHE II and SOFA, and bootstrap confidence intervals, assessed robustness. Secondary analyses included the examination of admission discrimination (ROC/AUC), a leave-one-out cross-validated combined model, and longitudinal trajectories. All analyses were exploratory, hypothesis-generating, and unadjusted for multiple comparisons unless stated. Results: Hierarchical clustering identified a coherent cluster comprising GDF-15, IGFBP-1, IGFBP-2, and growth hormone-binding protein (GHBP), distinct from classical GH-resistance markers (GHR vs. healthy controls, GHR vs. admission) and from GH, IGF-1, acid-labile subunit (ALS), and IGFBP-3. Within this cluster, GDF-15 correlated with IGFBP-1 (ρ = 0.65, 95% bootstrap CI 0.44–0.78), IGFBP-2 (ρ = 0.50, CI 0.19–0.71), and GHBP (ρ = 0.47, CI 0.20–0.68); GDF-15 showed no correlation with classical GH-resistance markers. These correlations were essentially unchanged after adjusting for APACHE II or SOFA (partial ρ within 0.03–0.16 of unadjusted values), indicating the structure is not attributable to shared confounding by illness severity. This robustness extended to further adjustment for IL-6, age, BMI, and mechanical-ventilation duration, and results from all 45 pairwise T01 correlations were re-examined with Benjamini–Hochberg false-discovery-rate correction (9 of 11 nominally significant pairs retained q < 0.05). However, the GDF-15–GHBP correlation, unlike the GDF-15–IGFBP-1/IGFBP-2 correlations, attenuated substantially after adjustment for IL-6 and was not consistent across a brain-injury/non-brain-injury subgroup sensitivity analysis, indicating this specific link is less specific than the others. In secondary exploratory analyses, GDF-15 had the highest individual admission AUC (0.74) among biomarkers but was substantially outperformed by APACHE II (AUC 0.90) and SOFA (AUC 0.81); a combined GDF-15 + IGFBP-2 model did not improve on GDF-15 alone. Conclusions: This study identifies a severity-independent intercorrelation structure linking GDF-15 to inhibitory IGFBPs, distinct from classical GH-resistance signaling, in critically ill patients. Although the findings do not support any clinical application at this stage, further study in adequately powered, multicenter cohorts can be contemplated.
Open AccessGrowth Hormone–Insulin-like Growth Factor Axis and GDF-15 in Critical Illness: Implications for Survival Stratification
Background: The growth hormone (GH)–insulin-like growth factor (IGF) axis is profoundly dysregulated in critical illness. GDF-15 and individual IGF-binding proteins (IGFBPs) have separately been proposed as prognostic biomarkers, but to our knowledge, no prior study has simultaneously characterized all major GH–IGF axis components and GDF-15 in the same critically ill cohort, precluding assessment of their joint intercorrelation structure. Aim: To provide the first simultaneous characterization of the intercorrelation structure among ten GH–IGF axis components and GDF-15 in a single ICU cohort, testing whether this structure is robust to adjustment for illness severity; and, secondarily, to describe admission discriminatory performance relative to APACHE II and SOFA. Methods: This was a prospective observational pilot study of 43 critically ill adults with admission (T01) measurement of ten GH–IGF axis biomarkers and longitudinal follow-up to day 15. Spearman correlations and hierarchical clustering characterized the admission intercorrelation structure; partial correlations adjusting for APACHE II and SOFA, and bootstrap confidence intervals, assessed robustness. Secondary analyses included the examination of admission discrimination (ROC/AUC), a leave-one-out cross-validated combined model, and longitudinal trajectories. All analyses were exploratory, hypothesis-generating, and unadjusted for multiple comparisons unless stated. Results: Hierarchical clustering identified a coherent cluster comprising GDF-15, IGFBP-1, IGFBP-2, and growth hormone-binding protein (GHBP), distinct from classical GH-resistance markers (GHR vs. healthy controls, GHR vs. admission) and from GH, IGF-1, acid-labile subunit (ALS), and IGFBP-3. Within this cluster, GDF-15 correlated with IGFBP-1 (ρ = 0.65, 95% bootstrap CI 0.44–0.78), IGFBP-2 (ρ = 0.50, CI 0.19–0.71), and GHBP (ρ = 0.47, CI 0.20–0.68); GDF-15 showed no correlation with classical GH-resistance markers. These correlations were essentially unchanged after adjusting for APACHE II or SOFA (partial ρ within 0.03–0.16 of unadjusted values), indicating the structure is not attributable to shared confounding by illness severity. This robustness extended to further adjustment for IL-6, age, BMI, and mechanical-ventilation duration, and results from all 45 pairwise T01 correlations were re-examined with Benjamini–Hochberg false-discovery-rate correction (9 of 11 nominally significant pairs retained q < 0.05). However, the GDF-15–GHBP correlation, unlike the GDF-15–IGFBP-1/IGFBP-2 correlations, attenuated substantially after adjustment for IL-6 and was not consistent across a brain-injury/non-brain-injury subgroup sensitivity analysis, indicating this specific link is less specific than the others. In secondary exploratory analyses, GDF-15 had the highest individual admission AUC (0.74) among biomarkers but was substantially outperformed by APACHE II (AUC 0.90) and SOFA (AUC 0.81); a combined GDF-15 + IGFBP-2 model did not improve on GDF-15 alone. Conclusions: This study identifies a severity-independent intercorrelation structure linking GDF-15 to inhibitory IGFBPs, distinct from classical GH-resistance signaling, in critically ill patients. Although the findings do not support any clinical application at this stage, further study in adequately powered, multicenter cohorts can be contemplated.
- Open Access
Longitudinal Trajectories of Resting Energy Expenditure, Cortisol and IGF-1, and Disease Severity in Critically Ill Patients: A Prospective Pilot Study
Background/Objectives: Resting energy expenditure (REE) rises during critical illness, but its determinants and prognostic relevance remain incompletely characterized. Identifying a circulating signal that tracks REE could provide a bedside surrogate for metabolic demand where indirect calorimetry is unavailable. This prospective pilot study described longitudinal trajectories of indirect calorimetry-measured REE, Sequential Organ Failure Assessment (SOFA) score, serum cortisol and insulin-like growth factor-1 (IGF-1) over two weeks in the intensive care unit (ICU), examined whether the REE trajectory was attenuated by adjustment for these variables, and generated preliminary effect-size and variance estimates for mortality. Methods: This single-center pilot study enrolled 39 critically ill adults at Evangelismos General Hospital (Athens, Greece); sample size was pragmatic, not based on an a priori power calculation. REE (Q-NRG metabolic monitor), cortisol and IGF-1 were measured at admission and days 5–7, 10–11 and 13–14, alongside SOFA. Trajectories were modeled with linear mixed-effects models using all available repeated measures. Confounding was assessed by adding SOFA, cortisol and IGF-1 as covariates and evaluating attenuation of the time effect; no formal mediation analysis was performed. Causes of missing data were quantified and a completers-only sensitivity analysis was undertaken. Mortality was analyzed by Cox regression with ICU length of stay as the time variable. Estimation was emphasized throughout; point estimates and 95% confidence intervals (CIs) are reported in preference to significance testing. Results: Mean age was 54.6 ± 18.1 years; 69.2% were male; median admission SOFA was 6 (IQR 3–9). ICU and 28-day mortality were 20.5% (8/39) and 10.3% (4/39). REE/kg rose from 25.3 ± 3.7 to a peak of 27.2 ± 4.2 kcal/kg/day by days 10–11 (likelihood-ratio χ2 = 17.2, p = 0.0006). Attrition was driven predominantly by discharge alive (18 of 23 patients missing at days 13–14) rather than death (n = 2), and the trajectory was preserved in a completers-only sensitivity analysis (χ2 = 9.13, p = 0.028). Cortisol declined (21.1 to 13.4 μg/dL) and IGF-1 rose (80.0 to 105.4 ng/mL); SOFA was essentially unchanged. REE did not correlate with SOFA, cortisol or IGF-1 at any time-point, and the time effect was not attenuated by adjustment for them. Admission REE was not associated with ICU mortality (HR 1.00, 95% CI 1.00–1.00). Higher admission REE was associated with a longer ICU stay, and this persisted after adjustment for body mass index (p = 0.026) and fat-free mass (p = 0.001). Age (HR 1.04, 95% CI 1.00–1.09) and admission SOFA (HR 1.18, 95% CI 0.98–1.44) were the covariates most associated with ICU mortality. Conclusions: REE rose progressively over the first 10–11 days of critical illness. Its trajectory was not attenuated by adjustment for SOFA, cortisol or IGF-1, which is compatible with—but does not establish—independence from the adrenal and somatotropic markers measured here. Neither REE nor these hormones were associated with mortality; age and disease severity remained the dominant prognostic factors, supporting a larger confirmatory study.
Open AccessLongitudinal Trajectories of Resting Energy Expenditure, Cortisol and IGF-1, and Disease Severity in Critically Ill Patients: A Prospective Pilot Study
Background/Objectives: Resting energy expenditure (REE) rises during critical illness, but its determinants and prognostic relevance remain incompletely characterized. Identifying a circulating signal that tracks REE could provide a bedside surrogate for metabolic demand where indirect calorimetry is unavailable. This prospective pilot study described longitudinal trajectories of indirect calorimetry-measured REE, Sequential Organ Failure Assessment (SOFA) score, serum cortisol and insulin-like growth factor-1 (IGF-1) over two weeks in the intensive care unit (ICU), examined whether the REE trajectory was attenuated by adjustment for these variables, and generated preliminary effect-size and variance estimates for mortality. Methods: This single-center pilot study enrolled 39 critically ill adults at Evangelismos General Hospital (Athens, Greece); sample size was pragmatic, not based on an a priori power calculation. REE (Q-NRG metabolic monitor), cortisol and IGF-1 were measured at admission and days 5–7, 10–11 and 13–14, alongside SOFA. Trajectories were modeled with linear mixed-effects models using all available repeated measures. Confounding was assessed by adding SOFA, cortisol and IGF-1 as covariates and evaluating attenuation of the time effect; no formal mediation analysis was performed. Causes of missing data were quantified and a completers-only sensitivity analysis was undertaken. Mortality was analyzed by Cox regression with ICU length of stay as the time variable. Estimation was emphasized throughout; point estimates and 95% confidence intervals (CIs) are reported in preference to significance testing. Results: Mean age was 54.6 ± 18.1 years; 69.2% were male; median admission SOFA was 6 (IQR 3–9). ICU and 28-day mortality were 20.5% (8/39) and 10.3% (4/39). REE/kg rose from 25.3 ± 3.7 to a peak of 27.2 ± 4.2 kcal/kg/day by days 10–11 (likelihood-ratio χ2 = 17.2, p = 0.0006). Attrition was driven predominantly by discharge alive (18 of 23 patients missing at days 13–14) rather than death (n = 2), and the trajectory was preserved in a completers-only sensitivity analysis (χ2 = 9.13, p = 0.028). Cortisol declined (21.1 to 13.4 μg/dL) and IGF-1 rose (80.0 to 105.4 ng/mL); SOFA was essentially unchanged. REE did not correlate with SOFA, cortisol or IGF-1 at any time-point, and the time effect was not attenuated by adjustment for them. Admission REE was not associated with ICU mortality (HR 1.00, 95% CI 1.00–1.00). Higher admission REE was associated with a longer ICU stay, and this persisted after adjustment for body mass index (p = 0.026) and fat-free mass (p = 0.001). Age (HR 1.04, 95% CI 1.00–1.09) and admission SOFA (HR 1.18, 95% CI 0.98–1.44) were the covariates most associated with ICU mortality. Conclusions: REE rose progressively over the first 10–11 days of critical illness. Its trajectory was not attenuated by adjustment for SOFA, cortisol or IGF-1, which is compatible with—but does not establish—independence from the adrenal and somatotropic markers measured here. Neither REE nor these hormones were associated with mortality; age and disease severity remained the dominant prognostic factors, supporting a larger confirmatory study.
- Open Access
- 11 June 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (6) , 1324
Circulating Novel Adipokines in Critically Ill Patients with and Without Sepsis
Background/Objectives: Adipokines are candidate biomarkers in critical illness due to their roles in immunity and metabolism, both profoundly altered in sepsis. Omentin-1, vaspin, and chemerin have been studied in selected septic cohorts, but not concurrently in a heterogeneous ICU population including both septic and non-septic patients. Methods: Prospective observational cohort of 200 consecutive ICU patients with 28-day follow-up. Biomarkers were measured by ELISA within 24 h of admission. Analyses included Mann–Whitney U tests, Spearman correlations, ROC curves, and logistic regression with APACHE II and SOFA as comparators. Results: Vaspin was significantly higher in septic versus non-septic patients (406.4 [190.0–799.6] vs. 275.8 [101.8–559.8] pg/mL; p = 0.009). Omentin-1 was elevated in 28-day non-survivors (34.4 [22.5–56.1] vs. 25.1 [15.0–48.4] ng/mL; p = 0.037; AUROC 0.599), but lost significance after APACHE II adjustment (p = 0.295). Chemerin trended lower in non-survivors (p = 0.099); in septic patients, it correlated inversely with SOFA (r = −0.43) and lactate (r = −0.40), both p < 0.001. IL-6 and IL-10 were higher in non-survivors; IL-10 predicted 28-day mortality (AUROC 0.783), comparable to APACHE II (0.785). Conclusions: Vaspin distinguishes sepsis in mixed ICU populations. Omentin-1 shows a severity-driven association with mortality that does not survive APACHE II adjustment (AUROC 0.599, poor standalone discrimination), while chemerin inversely tracks hypoperfusion markers in septic patients, suggesting a potential counter-regulatory role requiring mechanistic confirmation. Individually, these adipokines do not add prognostic value beyond established severity scores, but their biological orthogonality to classical cytokines warrants exploration in multi-marker panel studies.
- 11 June 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (6) , 1324
Open AccessCirculating Novel Adipokines in Critically Ill Patients with and Without Sepsis
Background/Objectives: Adipokines are candidate biomarkers in critical illness due to their roles in immunity and metabolism, both profoundly altered in sepsis. Omentin-1, vaspin, and chemerin have been studied in selected septic cohorts, but not concurrently in a heterogeneous ICU population including both septic and non-septic patients. Methods: Prospective observational cohort of 200 consecutive ICU patients with 28-day follow-up. Biomarkers were measured by ELISA within 24 h of admission. Analyses included Mann–Whitney U tests, Spearman correlations, ROC curves, and logistic regression with APACHE II and SOFA as comparators. Results: Vaspin was significantly higher in septic versus non-septic patients (406.4 [190.0–799.6] vs. 275.8 [101.8–559.8] pg/mL; p = 0.009). Omentin-1 was elevated in 28-day non-survivors (34.4 [22.5–56.1] vs. 25.1 [15.0–48.4] ng/mL; p = 0.037; AUROC 0.599), but lost significance after APACHE II adjustment (p = 0.295). Chemerin trended lower in non-survivors (p = 0.099); in septic patients, it correlated inversely with SOFA (r = −0.43) and lactate (r = −0.40), both p < 0.001. IL-6 and IL-10 were higher in non-survivors; IL-10 predicted 28-day mortality (AUROC 0.783), comparable to APACHE II (0.785). Conclusions: Vaspin distinguishes sepsis in mixed ICU populations. Omentin-1 shows a severity-driven association with mortality that does not survive APACHE II adjustment (AUROC 0.599, poor standalone discrimination), while chemerin inversely tracks hypoperfusion markers in septic patients, suggesting a potential counter-regulatory role requiring mechanistic confirmation. Individually, these adipokines do not add prognostic value beyond established severity scores, but their biological orthogonality to classical cytokines warrants exploration in multi-marker panel studies.
- Open Access
- 18 June 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (12) , 1463
Phase Angle Trajectory Among Critical Care Patients: Longitudinal Decline Predicts Mortality Independent of Clinical Severity Scores
Background/Objectives: The phase angle (PhA) is an emerging biomarker reflecting the cellular integrity and nutritional status. This study aimed to explore potential associations between the PhA, clinical severity scores, and 60-day survival outcomes following an admission to the Intensive Care Unit (ICU). Methods: This prospective, single-center study included 43 critically ill patients admitted to the ICU at Evangelismos General Hospital between May and November 2024. Patients were stratified by their PhA (≤5.4° vs. >5.4°). The PhA was measured at admission and subsequently on days 5–7, 10–11, 13–14, and until discharge. Severity scores (SOFA and APACHE II) were recorded. Between-group differences were assessed using independent samples t-tests and Mann–Whitney U tests, as appropriate. Survival was analyzed using Kaplan–Meier curves and Cox proportional hazards models. Results: The mean age was 54.6 ± 17 years; 63.6% were male. At ICU admission, patients with a PhA > 5.4° were significantly younger (p < 0.001) and had a higher fat-free mass (p < 0.001), greater calf circumference (p < 0.001), higher extracellular water (p < 0.001), larger mid-upper arm circumference (p = 0.009), and higher resting energy expenditure per kilogram (27.4 vs. 23.1 kcal/kg, p = 0.002). The PhA declined significantly during the ICU stay (p < 0.001). The Kaplan–Meier analysis showed a significantly shorter survival in patients with a PhA ≤ 5.4° (HR: 6.32, p = 0.019), which remained significant after adjusting for sepsis (p = 0.017). In a multivariable Cox regression, both PhA and APACHE II scores independently predicted mortality. Conclusions: While limited by a small sample size and single-center design, these findings support the further exploration of the PhA as a monitoring tool in critical care.
- 18 June 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (12) , 1463
Open AccessPhase Angle Trajectory Among Critical Care Patients: Longitudinal Decline Predicts Mortality Independent of Clinical Severity Scores
Background/Objectives: The phase angle (PhA) is an emerging biomarker reflecting the cellular integrity and nutritional status. This study aimed to explore potential associations between the PhA, clinical severity scores, and 60-day survival outcomes following an admission to the Intensive Care Unit (ICU). Methods: This prospective, single-center study included 43 critically ill patients admitted to the ICU at Evangelismos General Hospital between May and November 2024. Patients were stratified by their PhA (≤5.4° vs. >5.4°). The PhA was measured at admission and subsequently on days 5–7, 10–11, 13–14, and until discharge. Severity scores (SOFA and APACHE II) were recorded. Between-group differences were assessed using independent samples t-tests and Mann–Whitney U tests, as appropriate. Survival was analyzed using Kaplan–Meier curves and Cox proportional hazards models. Results: The mean age was 54.6 ± 17 years; 63.6% were male. At ICU admission, patients with a PhA > 5.4° were significantly younger (p < 0.001) and had a higher fat-free mass (p < 0.001), greater calf circumference (p < 0.001), higher extracellular water (p < 0.001), larger mid-upper arm circumference (p = 0.009), and higher resting energy expenditure per kilogram (27.4 vs. 23.1 kcal/kg, p = 0.002). The PhA declined significantly during the ICU stay (p < 0.001). The Kaplan–Meier analysis showed a significantly shorter survival in patients with a PhA ≤ 5.4° (HR: 6.32, p = 0.019), which remained significant after adjusting for sepsis (p = 0.017). In a multivariable Cox regression, both PhA and APACHE II scores independently predicted mortality. Conclusions: While limited by a small sample size and single-center design, these findings support the further exploration of the PhA as a monitoring tool in critical care.
- Open Access
- 7 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1406
Aquaporins in Acute Brain Injury: Insights from Clinical and Experimental Studies
Aquaporins (AQPs) are a family of transmembrane water channel proteins facilitating the transport of water and, in some cases, small solutes such as glycerol, lactate, and urea. In the central nervous system (CNS), several aquaporins play crucial roles in maintaining water homeostasis, modulating cerebrospinal fluid (CSF) circulation, regulating energy metabolism, and facilitating neuroprotection under pathological conditions. Among them, AQP2, AQP4, AQP9, and AQP11 have been implicated in traumatic and non-traumatic brain injuries. The most abundant aquaporin (AQP) in the brain, AQP4, is essential for fluid regulation, facilitating water transport across the blood–brain barrier and glymphatic clearance. AQP2 is primarily known for its function in the kidneys, but it is also expressed in brain regions related to vasopressin signaling and CSF dynamics. AQP9 acts as a channel for glycerol and lactate, thus playing a role in metabolic adaptation during brain injury. AQP11, an intracellular aquaporin, is involved in oxidative stress responses and cellular homeostasis, with emerging evidence suggesting its role in neuroprotection. Aquaporins play a dual role in brain injury; while they help maintain homeostasis, their dysregulation can exacerbate cerebral edema, metabolic dysfunction, and inflammation. In traumatic brain injury (TBI), aquaporins regulate the formation and resolution of cerebral edema. In non-traumatic brain injuries, including ischemic stroke, aneurysmal subarachnoid hemorrhage (aSAH), and intracerebral hemorrhage (ICH), aquaporins influence fluid balance, energy metabolism, and oxidative stress responses. Understanding the specific roles of AQP2, AQP4, AQP9, and AQP11 in these brain injuries may lead to new therapeutic strategies to mitigate secondary damage and improve neurological outcomes. This review explores the function of the above aquaporins in both traumatic and non-traumatic brain injuries, highlighting their potential and limitations as therapeutic targets for neuroprotection and recovery.
- 7 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1406
Open AccessAquaporins in Acute Brain Injury: Insights from Clinical and Experimental Studies
Aquaporins (AQPs) are a family of transmembrane water channel proteins facilitating the transport of water and, in some cases, small solutes such as glycerol, lactate, and urea. In the central nervous system (CNS), several aquaporins play crucial roles in maintaining water homeostasis, modulating cerebrospinal fluid (CSF) circulation, regulating energy metabolism, and facilitating neuroprotection under pathological conditions. Among them, AQP2, AQP4, AQP9, and AQP11 have been implicated in traumatic and non-traumatic brain injuries. The most abundant aquaporin (AQP) in the brain, AQP4, is essential for fluid regulation, facilitating water transport across the blood–brain barrier and glymphatic clearance. AQP2 is primarily known for its function in the kidneys, but it is also expressed in brain regions related to vasopressin signaling and CSF dynamics. AQP9 acts as a channel for glycerol and lactate, thus playing a role in metabolic adaptation during brain injury. AQP11, an intracellular aquaporin, is involved in oxidative stress responses and cellular homeostasis, with emerging evidence suggesting its role in neuroprotection. Aquaporins play a dual role in brain injury; while they help maintain homeostasis, their dysregulation can exacerbate cerebral edema, metabolic dysfunction, and inflammation. In traumatic brain injury (TBI), aquaporins regulate the formation and resolution of cerebral edema. In non-traumatic brain injuries, including ischemic stroke, aneurysmal subarachnoid hemorrhage (aSAH), and intracerebral hemorrhage (ICH), aquaporins influence fluid balance, energy metabolism, and oxidative stress responses. Understanding the specific roles of AQP2, AQP4, AQP9, and AQP11 in these brain injuries may lead to new therapeutic strategies to mitigate secondary damage and improve neurological outcomes. This review explores the function of the above aquaporins in both traumatic and non-traumatic brain injuries, highlighting their potential and limitations as therapeutic targets for neuroprotection and recovery.
- 26 February 2025
- Published by Elsevier in Advances in Medical Sciences
- Vol. 70 (1) , 191-196
High levels of soluble neuropilin−1 in critically ill multiple trauma/surgical patients
- 26 February 2025
- Published by Elsevier in Advances in Medical Sciences
- Vol. 70 (1) , 191-196
High levels of soluble neuropilin−1 in critically ill multiple trauma/surgical patients
- Open Access
Exploring Aquaporins in Human Studies: Mechanisms and Therapeutic Potential in Critical Illness
Aquaporins (AQPs) are membrane proteins facilitating water and other small solutes to be transported across cell membranes. They are crucial in maintaining cellular homeostasis by regulating water permeability in various tissues. Moreover, they regulate cell migration, signaling pathways, inflammation, tumor growth, and metastasis. In critically ill patients, such as trauma, sepsis, and patients with acute respiratory distress syndrome (ARDS), which are frequently encountered in intensive care units (ICUs), water transport regulation is crucial for maintaining homeostasis, as dysregulation can lead to edema or dehydration, with the latter also implicating hemodynamic compromise. Indeed, AQPs are involved in fluid transport in various organs, including the lungs, kidneys, and brain, where their dysfunction can exacerbate conditions like ARDS, acute kidney injury (AKI), or cerebral edema. In this review, we discuss the implication of AQPs in the clinical entities frequently encountered in ICUs, such as systemic inflammation and sepsis, ARDS, AKI, and brain edema due to different types of primary brain injury from a clinical perspective. Current and possible future therapeutic implications are also considered.
Open AccessExploring Aquaporins in Human Studies: Mechanisms and Therapeutic Potential in Critical Illness
Aquaporins (AQPs) are membrane proteins facilitating water and other small solutes to be transported across cell membranes. They are crucial in maintaining cellular homeostasis by regulating water permeability in various tissues. Moreover, they regulate cell migration, signaling pathways, inflammation, tumor growth, and metastasis. In critically ill patients, such as trauma, sepsis, and patients with acute respiratory distress syndrome (ARDS), which are frequently encountered in intensive care units (ICUs), water transport regulation is crucial for maintaining homeostasis, as dysregulation can lead to edema or dehydration, with the latter also implicating hemodynamic compromise. Indeed, AQPs are involved in fluid transport in various organs, including the lungs, kidneys, and brain, where their dysfunction can exacerbate conditions like ARDS, acute kidney injury (AKI), or cerebral edema. In this review, we discuss the implication of AQPs in the clinical entities frequently encountered in ICUs, such as systemic inflammation and sepsis, ARDS, AKI, and brain edema due to different types of primary brain injury from a clinical perspective. Current and possible future therapeutic implications are also considered.
- Open Access
- 6 December 2024
- Published by MDPI AG in Preprints.org
Exploring Aquaporins in Human Studies: Mechanisms and Therapeutic Potential in Critical Illness
Aquaporins (AQPs) are membrane proteins facilitating water and other small solutes to be transported across cell membranes. They are crucial in maintaining cellular homeostasis by regulating water permeability in various tissues. Moreover, they regulate cell migration, signaling pathways, inflammation, tumor growth, and metastasis. In critically ill patients, such as trauma, sepsis, and patients with acute respiratory distress syndrome (ARDS), which are frequently encountered in intensive care units (ICUs), water transport regulation is crucial for maintaining homeostasis, as dysregulation can lead to edema or dehydration, with the latter also implicating hemodynamic compromise. Indeed, AQPs are involved in fluid transport in various organs, including the lungs, kidneys, and brain, where their dysfunction can exacerbate conditions like ARDS, acute kidney injury (AKI), or cerebral edema. In this review, we discuss the implication of AQPs in the clinical entities frequently encountered in ICUs, such as systemic inflammation and sepsis, ARDS, acute kidney injury (AKI), and brain edema due to different types of primary brain injury from a clinical perspective. Current and possible future therapeutic implications are also considered.
- 6 December 2024
- Published by MDPI AG in Preprints.org
Open AccessExploring Aquaporins in Human Studies: Mechanisms and Therapeutic Potential in Critical Illness
Aquaporins (AQPs) are membrane proteins facilitating water and other small solutes to be transported across cell membranes. They are crucial in maintaining cellular homeostasis by regulating water permeability in various tissues. Moreover, they regulate cell migration, signaling pathways, inflammation, tumor growth, and metastasis. In critically ill patients, such as trauma, sepsis, and patients with acute respiratory distress syndrome (ARDS), which are frequently encountered in intensive care units (ICUs), water transport regulation is crucial for maintaining homeostasis, as dysregulation can lead to edema or dehydration, with the latter also implicating hemodynamic compromise. Indeed, AQPs are involved in fluid transport in various organs, including the lungs, kidneys, and brain, where their dysfunction can exacerbate conditions like ARDS, acute kidney injury (AKI), or cerebral edema. In this review, we discuss the implication of AQPs in the clinical entities frequently encountered in ICUs, such as systemic inflammation and sepsis, ARDS, acute kidney injury (AKI), and brain edema due to different types of primary brain injury from a clinical perspective. Current and possible future therapeutic implications are also considered.
- 1 November 2024
- Vol. 28 (22) , 4561-4575
The dead space fraction as a prognostic death indicator in patients with ARDS: a systematic review and meta-analysis.
Acute respiratory distress syndrome (ARDS) is a systemic disease with high morbidity and mortality. Dead space fraction (Vd/Vt) represents the volume of air that does not participate in gas exchange and accurately depicts the pathophysiology of ARDS due to ventilation and perfusion mismatch. In this study, we aim to conduct a systematic review and meta-analysis regarding its usefulness for predicting mortality. We performed a systematic literature search identifying comparative studies meeting the above criteria from four databases: MEDLINE, clinicaltrials.gov, CENTRAL, and Google Scholar. A statistical meta-analysis was conducted utilizing the "meta" package in R software, with the included studies assessed based on the Newcastle-Ottawa scale. A total of twelve studies were included and data from over 1,700 patients was collected. Patients with higher levels of Vd/Vt were more likely to not survive with an OR=1.27 [95% CI (1.09, 1.48), I2=93%, p<0.01]. In addition, non-survivors of ARDS had higher mean value levels of Vd/Vt than survivors with an MD=0.07 [95% CI (0.02, 0.11), I2=82%, p<0.01]. Furthermore, a leave-one-out meta-analysis was performed in order to assess the effect of each individual study on the overall outcome, which led to the lowering of heterogeneity to 0. The Vd/Vt ratio is an accurate index for determining the mortality of ARDS, reflecting the severity of the disease.
- 1 November 2024
- Vol. 28 (22) , 4561-4575
The dead space fraction as a prognostic death indicator in patients with ARDS: a systematic review and meta-analysis.
Acute respiratory distress syndrome (ARDS) is a systemic disease with high morbidity and mortality. Dead space fraction (Vd/Vt) represents the volume of air that does not participate in gas exchange and accurately depicts the pathophysiology of ARDS due to ventilation and perfusion mismatch. In this study, we aim to conduct a systematic review and meta-analysis regarding its usefulness for predicting mortality. We performed a systematic literature search identifying comparative studies meeting the above criteria from four databases: MEDLINE, clinicaltrials.gov, CENTRAL, and Google Scholar. A statistical meta-analysis was conducted utilizing the "meta" package in R software, with the included studies assessed based on the Newcastle-Ottawa scale. A total of twelve studies were included and data from over 1,700 patients was collected. Patients with higher levels of Vd/Vt were more likely to not survive with an OR=1.27 [95% CI (1.09, 1.48), I2=93%, p<0.01]. In addition, non-survivors of ARDS had higher mean value levels of Vd/Vt than survivors with an MD=0.07 [95% CI (0.02, 0.11), I2=82%, p<0.01]. Furthermore, a leave-one-out meta-analysis was performed in order to assess the effect of each individual study on the overall outcome, which led to the lowering of heterogeneity to 0. The Vd/Vt ratio is an accurate index for determining the mortality of ARDS, reflecting the severity of the disease.